Frontiers in pharmacology · 2025
Analysis of six CYP450 genetic variants regarding the response to cannabidiol combined with anticonvulsant medication in mexican patients with drug-resistant epilepsy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Feria-Romero Iris A, Rocha Luisa, Reyes-Cuayahuitl Araceli, Martínez-Juárez Iris, San-Juan Daniel, Escamilla-Nuñez Consuelo, Orozco-Suarez Sandra
Аннотация
BACKGROUND: Cannabidiol (CBD) reduces the frequency of seizures in individuals with specific epileptic syndromes, but its effectiveness for other types of drug-resistant epilepsy (DRE) is unclear. CYP450 enzymes primarily metabolize CBD. The aim of this study was to identify CYP450 genotypes regarding the response of CBD treatment concomitant with anti-seizure drugs in patients with DRE.
METHODS: This observational, retrospective, comparative study examined patients with DRE who incorporated CBD into their treatment. Genomic DNA was extracted from the patients' blood. Patients were divided into two groups: CBD responders and CBD non-responders. Six genetic variants of CYP450 genes were analyzed using real-time polymerase chain reaction (PCR). Statistical significance was determined using Fisher's exact, chi-squared, and Mann-Whitney U tests. The analysis of polymorphisms involved a statistical test for proportion differences of more than 10% between the comparison groups.
RESULTS: This study examined 47 patients with DRE, of which 68% showed a positive response to CBD treatment in combination with their current medications. Among the patients who did not respond to adjuvant treatment with CBD, the CYP3A4 *1/rs2242480 genotype was present in 50%. These patients exhibited focal seizures along with various lesions in imaging studies. In contrast, the CYP2B6 *1/*2 and *2/*2 genotypes were identified in 42% of patients with drug-resistant epilepsy who did respond to CBD treatment. These patients had unknown causes of their epilepsy and showed expected results in imaging studies.
CONCLUSION: Treatment with CBD reduced seizures in most patients (68%), which was independent of etiology and seizure type. The genotype CYP3A4 *1/rs2242480 may be associated with low response to CBD.
METHODS: This observational, retrospective, comparative study examined patients with DRE who incorporated CBD into their treatment. Genomic DNA was extracted from the patients' blood. Patients were divided into two groups: CBD responders and CBD non-responders. Six genetic variants of CYP450 genes were analyzed using real-time polymerase chain reaction (PCR). Statistical significance was determined using Fisher's exact, chi-squared, and Mann-Whitney U tests. The analysis of polymorphisms involved a statistical test for proportion differences of more than 10% between the comparison groups.
RESULTS: This study examined 47 patients with DRE, of which 68% showed a positive response to CBD treatment in combination with their current medications. Among the patients who did not respond to adjuvant treatment with CBD, the CYP3A4 *1/rs2242480 genotype was present in 50%. These patients exhibited focal seizures along with various lesions in imaging studies. In contrast, the CYP2B6 *1/*2 and *2/*2 genotypes were identified in 42% of patients with drug-resistant epilepsy who did respond to CBD treatment. These patients had unknown causes of their epilepsy and showed expected results in imaging studies.
CONCLUSION: Treatment with CBD reduced seizures in most patients (68%), which was independent of etiology and seizure type. The genotype CYP3A4 *1/rs2242480 may be associated with low response to CBD.